About NeuroMetrix
NeuroMetrix is a Healthcare company based in Woburn (United States) founded in 1996 by Shai N Gozani, and was acquired by ElectroCore in December 2024. Wearable technology for pain, nerve disease and sleep disorders. NeuroMetrix has raised $14.58 million across 6 funding rounds from investors including MIT, ElectroCore and 180 Degree Capital. The company has 26 employees. Its chief executive, as recorded, is Shai N Gozani. NeuroMetrix offers products and services including Quell Fibromyalgia and DPNCheck. Its focus areas include Life Sciences, Pain Management, Medical Devices and Therapeutic Devices. Its legal entity is NeuroMetrix, Inc. Its competitors include Electromedical Technologies, Enso Relief and Hollywog; 2 of its 3 listed competitors have raised funding.
Company details
NeuroMetrix develops wearable medical technology and point-of-care tests for chronic pain, nerve diseases, and sleep disorders. Products include Quell (wearable for pain relief), Sensus (neurostimulation device for diabetic neuropathy associated pain), DPN Check (test for diabetic neuropathy) and the Advance NCS platform for the performance of nerve conduction studies. Went public in 2004. Its Quell device stimulates the sensory nerves in the leg, with the signal traveling up to the brain. This signal in the brain releases endogenous opioids into the spine which provide relief from chronic pain.
- Headquarters Woburn, United States
- Employees 26
- Founders Shai N Gozani
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website neurometrix.com
- Social LinkedIn
- Acquired by ElectroCore (Dec 2024)
- Legal Name Neurometrix, Inc.
- Annual Revenue$3.03 M (USD)-49as on Dec 31, 2024
- Net Profit-$6.53 M (USD)-48as on Dec 31, 2023
- EBITDA-$8.78 M (USD)-23as on Dec 31, 2024
- Total Equity Funding$14.58M (USD)
in 6 rounds
- Latest Funding Round$21M (USD), Post-IPO
Jun 2016
- InvestorsMIT
& 9 more
- Employee Count26
- Acquired byElectroCore
(Dec 2024)
Products & Services of NeuroMetrix
NeuroMetrix offers a comprehensive portfolio of products and services, including Quell Fibromyalgia and DPNCheck.
Wearable neuromodulator to reduce fibromyalgia symptoms.
Rapid test for detecting peripheral neuropathies in patients.
Funding Insights of NeuroMetrix
NeuroMetrix has successfully raised a total of $14.58M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $21 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.58M
- Total Rounds 6
- Last Round Post-IPO — $21M
- First Round $2M
(Jan 2003)
- Investors Count 9
All 6 funding rounds of NeuroMetrix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $21M | Post-IPO | – | – | – |
| Dec 2015 | $13.8M | Post-IPO | – | – | – |
| May 2015 | $14.7M | Post-IPO | – | – | – |
| Sep 2009 | $18.69M | Post-IPO | – | – | |
| Apr 2004 | $12.58M | Series A | – | – | |
| Jan 2003 | $2M | Series A | – | – | – |
10 investors in total: 10 institutional.
Investors in NeuroMetrix
NeuroMetrix has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include MIT, ElectroCore and 180 Degree Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Investments are made in life sciences firms across all stages. | delphiventures.com | Menlo Park, United States | ||
Private equity firm focused on company buyouts | gppfunds.com | Greenwich, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Private equity investments are targeted in the US and Canada. | symmetriccapital.com | Burlington, United States | ||
| whitney.com | ||||
Tech & offline focused VC firm investing in early & growth stage startups in the US | commonwealthvc.com | Woburn, United States | ||
VC firm funding companies in the US | 1981 | 180degreecapital.com | Montclair, United States | |
MIT is recognized as a leading institution for education and research. | 1861 | mit.edu | United States | |
Non-invasive vagus nerve stimulation devices are developed for headache treatments. | 2005 | electrocore.com | Basking Ridge, United States |
Investor details for NeuroMetrix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NeuroMetrix
11 people are tracked at NeuroMetrix (3 in leadership, 5 in board & advisors, 3 in team); the tracked headcount is 26.
| Name | Role | Group |
|---|---|---|
Shai N Gozani | Founder & CEO | Leadership |
J. Breck Harmel | National Director of Sales, Neuromodulation | Leadership |
Thomas T. Higgins | Senior Vice President and Chief Financial Officer | Leadership |
Nancy E. Katz | Director | Board & advisors |
Steven R. Peskin | Advisor | Board & advisors |
Bradley M. Fluegel | Director | Board & advisors |
David E. Goodman | Director | Board & advisors |
David Van Avermaete | Director | Board & advisors |
Susan M. Bell | SVP, Population Health & Value Based Care | Team |
Trishelle Cannatella | Medical Representative | Team |
Jeff Hampton | Outside Sales Manager | Team |
Complete people profiles for NeuroMetrix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NeuroMetrix
5 dated milestones of NeuroMetrix across 28 years, from founding to its latest funding, stage changes and deals.
- Founded NeuroMetrix is founded.
- Funding First funding round of $2.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $21.0M.
- Exit Acquired by ElectroCore.
Competitors of NeuroMetrix
NeuroMetrix has 3 listed competitors in our database, 2 of them funded. They include Electromedical Technologies, Enso Relief and Hollywog.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| electromedtech.com | 2007 | Phoenix, United States | $105,000 | 7 | An electrotherapy device that helps reduce and eliminate chronic or acute pain | |
| ensorelief.com | 2013 | San Francisco, United States | $120,000 | A wearable neuromodulation device for pain relief is developed. | ||
| hollywog.com | 2009 | Chattanooga, United States | Provides wireless OTC TENS devices for pain relief and various health indications. |
Detailed competitors of NeuroMetrix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NeuroMetrix
The website of NeuroMetrix (neurometrix.com) receives about 2.9K visits a month.
- Monthly visits2.9K
▲ 11.2% vs previous month
Websites whose visitors overlap most with NeuroMetrix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| advancedbrainmonitoring.com | 100% | 8.6K | #2,607,775 | View details | |
| momentapharma.com | 54% | #11,284,544 | View details | ||
cnsindia.com | cnsindia.com | 53% | – |
Top companies in Pain Management
3 companies that operate in the same segment as NeuroMetrix (Pain Management) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neurometrix
Complete news archive for NeuroMetrix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NeuroMetrix
NeuroMetrix was founded in 1996 and raised its 1st funding round 7 years after it was founded.
NeuroMetrix is headquartered in Woburn, United States. It is registered at Woburn, Massachusetts, United States.
Shai N Gozani is the CEO of NeuroMetrix, as recorded in our data. They have also founded this company.
NeuroMetrix is a funded company, having raised a total of $14.58M across 6 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on Jan 2003.
NeuroMetrix has 26 employees.
Annual revenue of NeuroMetrix is $3.03M as on Dec 31, 2024.
NeuroMetrix develops wearable medical technology and point-of-care tests for chronic pain, nerve diseases, and sleep disorders. Products include Quell (wearable for pain relief), Sensus (neurostimulation device for diabetic neuropathy associated pain), DPN Check (test for diabetic neuropathy) and the Advance NCS platform for the performance of nerve conduction studies. Went public in 2004. Its Quell device stimulates the sensory nerves in the leg, with the signal traveling up to the brain. This signal in the brain releases endogenous opioids into the spine which provide relief from chronic pain.
NeuroMetrix's top competitors include Electromedical Technologies, Enso Relief and Hollywog.
NeuroMetrix offers Quell Fibromyalgia and DPNCheck.
NeuroMetrix has 10 investors. Key investors include MIT, ElectroCore, 180 Degree Capital, Deerfield, and Delphi Ventures.
NeuroMetrix operates through Neurometrix, Inc..
Yes. NeuroMetrix was acquired by ElectroCore in December 2024.